12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Poteligeo mogamulizumab: Phase II started

Under a 2008 deal, Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) has exclusive rights from Kyowa to develop and commercialize mogamulizumab for all non-cancer indications outside of Japan, Korea, China and Taiwan (see BioCentury, March 10, 2008). Eli Lilly and Co. (NYSE:LLY,...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >